Whalesbook
CDSCO Ka Naya Rule: Pharma Companies Ke Liye Kya Badla?
Dekho, pehle kya hota tha, jab koi naya drug approve ho jata tha na, toh uske safety reports (PSURs) tabhi se count hone lagte the. But asli problem yeh thi ki drug launch hone mein kaafi time lag jata tha. Iss lambe gap mein, jab patient use kar rahe hain woh data miss ho jata tha. Ab CDSCO ne yeh gap khatam kar diya hai.
Ab Safety Reporting Start Hogi Seedha Market Launch Se!
CDSCO ne rules change kar diye hain! Ab companies ko drug safety reports, jinko hum PSURs (Periodic Safety Update Reports) bolte hain, woh drug ke actual market launch date se submit karna shuru karna hoga, na ki approval date se. Iska simple matlab hai ki jab se log dawa use karna shuru karenge, tabhi se uski safety monitoring aur reporting start ho jayegi. Yeh sab taki patient safety par aur acchi nazar rakhi ja sake aur koi bhi valuable safety insights miss na ho. Isse India bhi global standards ke kareeb aa raha hai, jaise EMA (European Medicines Agency) mein hota hai.
Chhote Manufacturers Par Pressure Badha?
Yeh rule sunne mein toh achha lag raha hai, but pharma companies, especially chhote manufacturers, ke liye operational aur financial costs badh sakte hain. Ab unko launch ke time se hi strong data management aur safety monitoring systems ready rakhne padenge. Pehle se hi India mein GMP (Good Manufacturing Practices) jaise dusre regulatory changes bhi chal rahe hain, toh yeh naya rule un par aur pressure dalega. Agar market entry aur safety reporting systems align nahi hue toh penalties lag sakti hain. Kuch companies ko toh launch postpone bhi karna pad sakta hai jab tak unke systems ready na ho jayein.
India Pharma Market Aur Future
India ka pharma market already kaafi bada hai, around $65 billion by volume, aur $130 billion tak jaane ka estimate hai 2030 tak. Global standards ke saath align hona aur regulations ko samajhna ab aur bhi zaroori ho gaya hai. Companies ko ab PSUR planning ko launch strategy ka part banana padega. Agility hi kaam aayegi.